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The electrocardiogram shown above
demonstrates an arrhythmia, called torsades
de pointes (sinusoidal trace at right), that is
incompatible with the normal pump function
of the heart.  This particular case was drug-
induced and reflects the impairment of
specific potassium channels that normally
promote the repolarization phase of the
cardiac action potential. New insights into
the mutations and drugs that compromise the
cellular flux of potassium, not only in the
heart but also in other organs, are being
gained through investigations of the protein
components of voltage-gated potassium
channels.
Voltage-gated potassium channels provide tightlycontrolled, ion-specific pathways across membranes
and are key to the normal function of nerves and muscles.
They arise from the assembly of four pore-forming proteins
called α-subunits. To attain the properties of native currents,
α-subunits interact with additional molecules such as the
MinK-related peptides (MiRPs), single-transmembrane
subunits encoded by the KCNE genes. Significantly,
mutations in KCNE 1, 2, and 3 have been linked either to life-
threatening cardiac arrhythmia or a disorder of skeletal
muscle, familial periodic paralysis. The capacity of MiRPs to
partner with multiple α-subunits in experimental cells appears
to reflect still undiscovered roles for the KCNE-encoded
peptides in vivo. Here, we consider these unique peptides in
health and disease, and discuss future research directions.
Geoffrey W. Abbott and Steve A. N. Goldstein
Departments of Pediatrics and Cellular and
Molecular Physiology
Boyer Center for Molecular Medicine
Yale University School of Medicine
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INTRODUCTION
Potassium channels regulate fluid homeostasis, signaling in
nervous tissue, and muscular contraction.  This array of tasks is
achieved by the controlled and exquisitely timed opening and
closing of the water-filled channels through which potassium ions
diffuse across cell membranes (1).  For example, in the heart,
voltage-gated potassium (VGK) channels open in response to a
depolarizing wave of excitation that travels through the cells with
each beat. The resulting efflux of potassium ions repolarizes the
cells, thereby closing the channels and ending the
excitation–contraction cycle so that the muscle is prepared to beat
again.  Similarly, VGK channels in nerve cells facilitate rapid signal
transmission and limit excitatory influences.  These crucial
functions explain why drugs that act on potassium channels, and
mutations in channel genes, can have significant effects on human
physiology (2).
As shown in Figure 1, each of the four pore-forming α-
subunits of VGK channels has six  transmembrane (TM) segments
and a single pore (P) loop that includes the signature sequence
TXGY/FG (3).  The tetrameric assemblies form a single, central, ion-
selective pore that is lined by the four P loops and the TM segments
flanking each P loop in the primary structure (identified as S5 and
S6) (4–5).  The fourth TM segment of each α-subunit (S4) contains
periodic basic residues and acts as the voltage sensor (6–7).  In
general, the expression of an α-subunit subtype (e.g., KCNQ1,
HERG, or Kv3.4) gives rise to functional channels in experimental
cells such as Xenopus laevis oocytes or mammalian tissue cells in
culture.  The currents that arise from these α-subunits, however,
are often unlike the native currents manifested by cells in which
they are naturally expressed. One well-known explanation for this
disparity is the requirement for additional (sometimes called
“accessory” or β) subunits—some cytoplasmic, others that are
integral to the membrane—that modulate channel properties (8).
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Figure 1.  The KCNE genes encode single-
transmembrane–domain peptides (i.e., MiRPs) that
regulate voltage-gated potassium (VGK) channels.
VGK channels are formed by association of four α-
subunits (blue). Each α-subunit contains six
transmembrane domains and one pore-forming P loop (P;
see inset).  P loops contain the pentapeptide sequence
TXGY/FG at the ion selectivity filter portion of the pore. In
cells, potassium channel α-subunits interact with
additional subunits, such as MiRPs (red), as well as
membrane and cytosolic regulators (not shown). The
MiRPs are encoded by KCNE genes and are a family of β-
subunits that assemble (denoted by arrow) with α-
subunits to generate native channels. The stoichiometry
of MiRP subunits within each channel is not known; a
possible α4β2 complex is shown (looking down onto the
plane of the exterior membrane surface; right), suggesting
close approximation of MiRP and the ion conduction
pore (17, 73).
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The additionally required subunits that we describe here
are encoded by the KCNE gene family and consist of 103 to 177
residues, with a single TM domain.  These peptides associate
with α-subunits to form stable assemblies with unique
properties (Figure 1).  The family of peptides encoded by the
KCNE genes has five known members, three of which have been
characterized.  The founding member, MinK, is encoded by
KCNE1 and was discovered in 1988 by functional expression of
fractionated rat kidney RNA (9).  A decade later, KCNE2,
KCNE3, and KCNE4 were discovered by focusing on motifs in
MinK critical to function using homology-based searches of
expressed sequence tag databases; the corresponding gene
products were designated the MinK-Related Peptides (MiRPs) 1,
2, and 3 (Figure 2) (8–10).  KCNE5, encoding MiRP4, was
subsequently found in a gene-rich segment of DNA,  the
deletion of which results in a syndrome denoted as AMME (for
Alport syndrome, mental retardation, midface hypoplasia, and
elliptocytosis) (11).  MinK has been shown to function in the
heart and ear (2), MiRP1 in the heart (10, 12), and MiRP2 in
skeletal muscle (13), whereas roles for MiRP3 and MiRP4 are not
yet described.
MinK, MiRP1, and MiRP2 contribute to the function of VGK
channels by influencing channel gating (i.e., channel opening
and closing), ion selectivity, and ion flux rate (single channel
conductance); they also significantly affect the pharmacology,
regulation, and surface expression of VGK channels (10, 12–18).
Indeed, concurrent expression of MiRPs and α-subunits (e.g.,
MinK/KCNQ1, MiRP1/HERG, and MiRP2/Kv3.4) in experimental
systems recapitulates the properties of native currents (10, 13,
14), and mutations in KCNE1, KCNE2, and KCNE3 are associated
with inherited and acquired disease (10, 12, 13, 19–21). Here, we
consider the influence of MinK, MiRP1, and MiRP2 in native
potassium channels.  Other current reviews have addressed the
issues of MinK tissue distribution and regulation (22, 23),
structure–function relationships in MinK/KCNQ1 and
MiRP1/HERG complexes (8), and the controversial issue of
whether the MiRPs act through close juxtaposition with the
channel ion conduction pore (24, 25).
Potassium currents of four types contribute to the cardiac
action potential: transient outward (Ito), leak (IKp), delayed
rectifiers (IKr and IKs), and inward rectifier (IKir); see (32, 33).
Calcium and sodium channels are key to phase 0
depolarization (i.e., a positive shift in the cell voltage from
resting membrane potential). Ito currents are activated by this
depolarization to produce phase 1 repolarization, a partial
return toward resting potential as potassium leaves the cell
through channels, putatively formed by Kv1.4, Kv4.2 and/or
Kv4.3 subunits, that inactivate rapidly. The plateau of the
action potential (phase 2) is maintained by calcium and
potassium currents (variously called IKp, IKsus, or IKur) that
appear to be carried by Kv1.5 and/or KCNK-type 2–P-domain
leak channels (34). IKr and IKs, the delayed rectifiers, are
activated more slowly upon depolarization and return cells to rest during phase 3 repolarization; IKr and IKs appear to be carried
by MiRP1/HERG and MinK/KCNQ1 channels, respectively, as we discuss here.  The rise from rest to threshold (phase 4)
determines heart rate and is mediated by inwardly rectifying potassium currents (IKir) including IK1 (generated by Kir2.1-4
subunits), IKAch (attributed to Kir3.1 and Kir3.4 subunits) and IKATP (arising from Kir6.1 and SUR subunits) as well as a non-
selective cation current (IF) formed of HCN family subunits.
The majority of mutations and polymorphisms that have been associated with arrhythmia occur in genes for the delayed
rectifier channels IKr and IKs.  In these cases, arrhythmia results from reduction of potassium flux, impairing repolarization
capacity, and prolonging the cardiac action potential (see dashed line in Figure).  This prolongation is reflected on the surface
electrocardiogram as a long QT interval and predisposes patients to torsades de pointes* (TdP), ventricular fibrillation (VF), and
sudden death (35–37).  Reduced flux can result from channels with suboptimal gating kinetics (e.g., slow rates of opening or
passing ions, or increased rates of closing, perhaps effected by drugs); reduced flux can alternatively result from a reduced number
of channels in the plasma membrane.  Of the six loci that have been associated with long QT intervals, two have been identified as
KCNE genes (KCNE1 and KCNE2); two others have been ascribed to genes for the respective α-subunit partners (KCNQ1 and
HERG); one is linked to a sodium channel gene (SCN5A); and the final locus has not been correlated to a specific gene (38).
*Torsades de pointes: a ventricular tachycardia characterized by fluctuation of QRS complexes around the electrocardiographic
baseline.
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Figure: Potassium currents in the cardiac action potential.
MinK, THE KCNE1 GENE PRODUCT
When mRNA that encodes rat MinK is injected into Xenopus laevis
oocytes, a very slowly activating potassium current is observed that
is similar (but not identical) to the cardiac delayed rectifier current
IKs (9, 26).  That this 130-residue peptide appeared to form
channels on its own produced a controversy only later laid to rest
by the cloning of its pore-forming partner, KCNQ1.  Specifically,
the KCNQ1 gene (originally KvLQT1; first isolated by its linkage to
the cardiac rhythm disorder known as long QT syndrome) was
recognized to encode a classical VGK α-subunit (27).  The paired
expression of KCNQ1 with KCNE1 in experimental cells thus
reproduced currents that resembled the native IKs of cardiac
myocytes (14, 74).  MinK-induced currents in oocytes are thus
attributable to a Xenopus laevis ortholog of KCNQ1 (14).  Indeed,
MinK does not generate currents in cells, such as Chinese hamster
ovary (CHO) cells, that lack endogenous KCNQ1 (28).  In addition
to contributing to the formation of IKs channels with KCNQ1,
MinK may also influence the function of HERG (see section on
MiRP promiscuity, below) (39).  
The most apparent effect of MinK on KCNQ1 is an
approximately tenfold slowing of activation kinetics (Figure 3),
although MinK also alters inactivation and deactivation gating (17,
29).  Moreover, the unitary conductance of the MinK/KCNQ1
channels (in symmetric 140 mM potassium ions) is approximately
fourfold greater than that of homomeric KCNQ1 channels (17, 30).
MinK also alters selectivity for monovalent cations (16, 17),
sensitivity to both external and internal pore blockers (18, 31),
inhibition by class III anti-arrhythmic agents (i.e., potassium
channel blockers) (15), and activation by small-molecule regulators
(15). 
Inheritance of single missense mutations in KCNE1 leading to
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KCNE1 (MinK) ---------- ------MILS NTTAVTPFLT KLWQETVQQG GNMSGLARRS PRSSDGKLEA LYVLMVLGFF GFFTLGIMLS YIRSKKLEHS NDPFNVYIES
KCNE2 (MiRP1) ---------- MSTLSNFTQT LEDVFRRIFI TYMDNWRQNT TAEQEALQAK VDAENFYYVI LYLMVMIGMF SFIIVAILVS TVKSKRREHS NDPYHQYIVE
KCNE3 (MiRP2) --METTNGTE TWYESLHAVL KALNATLHSN LLCRPGPGLG PDNQTEERRA SLPGRDDNSY MYILFVMFLF AVTVGSLILG YTRSRKVDKR SDPYHVYIKN
KCNE4 (MiRP3) ---------- ---------- ----MLKMEP LNSTHPGTAA SSSPLESRAA GGGSGNGNEY FYILVVMSFY GIFLIGIMLG YMKSKRREKK SSLLLLYKDE
KCNE5 (MiRP4) MNCSESQRLR TLLSRLLLEL HHRGNASGLG AGPRPSMGMG VVPDPFVGRE VTSAKGDDAY LYILLIMIFY ACLAGGLILA YTRSRKLVEA KDEPSQACAE
KCNE1 (MinK) DAWQEKDKAY VQARVLESYR SCYVVENHLA IEQPNTHLPE TKPSP
KCNE2 (MiRP1) DWQEKYKSQI LNLEESKATI HENIGAAGFK MSP
KCNE3 (MiRP2) RVSMI
KCNE4 (MiRP3) ERLWGEAMKP LPVVSGLRSV QVPLMLNMLQ ESVAPALSCT LCSMEGDSVS SESSSPDVHL TIQEEGADDE LEETSETPLN ESSEGSSENI HQNS
KCNE5 (MiRP4) HEWAPGGALT ADAEAAAGSQ AEGRRQLASE GLPALAQGAE RV
Figure 2.  Alignment of amino acid sequences encoded by human KCNE1, 2, 3, 4, and 5. Predicted transmembrane domains are highlighted blue, and
highly conserved residues are highlighted yellow. Protein products are named in parentheses next to the respective genes.
KCNQ1
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Figure 3.  MinK associates with KCNQ1 to generate IKs. The human gene for the α-subunit KCNQ1 can be expressed (here in Xenopus laevis oocytes in
whole-cell mode) to generate functional VGK channels (left). Co-expression of MinK is required, however, to generate a current that is like IKs in cardiac
myocytes (right). Note that MinK greatly augments KCNQ1-mediated currents, and retards current activation. Cells were held at -80 mV and depolarized
for 5 s to voltages of -60 (red), -40 (green), -20 (yellow), 0 (purple), 20 (orange), 40 (blue), and 60 (pink) mV.
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the replacement of serine at position 74 with leucine, or aspartate
at position 76 with asparagine (Figure 4A) has been associated
with inherited long QT syndrome (17, 19–21, 40).  Mutations in
KCNE1 reduce net potassium flux by producing a positive shift in
the voltage dependence of activation (i.e., less current is generated
at a given level of depolarization), a reduction in the single channel
conductance, and accelerated deactivation (Figure 4B) (17).
Mutations in KCNE1 (and KCNQ1) have been implicated also in
predisposition to drug-induced long QT syndrome (50, 51). 
Individuals who carry two mutant alleles of KCNE1 can suffer
from a prolonged QT interval combined with sensorineural
deafness (i.e., Jervell and Lange-Nielsen syndrome; JLNS) (21, 40).
Congenital deafness in these cases stems from disrupted
production of endolymph due to defective IKs channels in the stria
vascularis in the cochlea (41).  Thus, a point mutation in KCNE1
has pathological consequences in multiple tissues, indicative of a
channel complex with multiple roles.  It should be noted that
KCNE1 transcripts are found in heart, auditory epithelium, kidney,
eye, gastrointestinal tract, and T cells (22, 23).
MiRP1, THE KCNE2 GENE PRODUCT
Even as HERG was becoming recognized as the likely molecular
correlate for IKr based on transcript levels and function, its failure
to fully recapitulate native IKr currents on its own led to the
suggestion that an additional subunit might be required (43).
Study of KCNE2 resolved the disparity between native and cloned
(i.e., homomeric) HERG channels; MiRP1 and HERG were found
to form stable complexes that behave like native IKr channels
(Figure 5) in terms of their unitary conductance, sensitivity to
external potassium ions, deactivation rate and, notably, inhibition
by the anti-arrhythmic agent E-4031; thus, homomeric HERG
channels were inhibited by E-4031 only in a use-dependent
fashion during repetitive pulse cycles, whereas MiRP1/HERG and
native IKr channels show tonic block (prior to the first activating
pulse) and ready relaxation to equilibrium blockade.  Although
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Figure 4.  Inherited mutations in the MinK-encoding gene KCNE1
compromise VGK currents and are associated with arrhythmia. 
A. Schematic of the MinK peptide indicating disease-associated mutations.
Residues highlighted in red represent missense mutations (i.e., S74L and
D76N) that have been functionally characterized and clinically associated
with arrhythmia (see text for details; also see panel B); residues highlighted
in yellow represent mutations that occur in individuals with arrhythmia
but that have not been functionally characterized (CHO, predicted sites of
glycosylation; P, predicted sites of phosphorylation).
B. Characterization of IKs current arising from mutant MinK. Currents
were studied in Xenopus laevis oocytes and measured in excised inside-out
patches in symmetrical 100 mM KCl.  The KCNQ1 protein was co-
expressed either with wild-type MinK or mutant form of MinK that is
associated with Jervell and Lange-Nielsen syndrome. Patches were held at 
-60 mV and depolarized for 6 s to voltages of 0 (red), 20 (green), 40
(yellow), 60 ( purple), and 80 (orange) mV.  (NB: The reduction in single
channel conductance associated with the mutant MinK is not indicated; see
text for details.)
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unitary conductance and gating kinetics were altered by MiRP1,
the distinctive gating attributes of HERG-containing channels were
qualitatively unchanged: With depolarization, the channels activate
but generate little outward current due to rapid inactivation; upon
repolarization, transition to the closed state is slow, allowing for
further ion flux (42). 
Consistent with a role in repolarization of the myocardium,
mutations that impair MiRP1 function are associated with inherited
cardiac arrhythmia (10).  Four mutations in KCNE2 have been
found that correlate to a prolonged QT interval and/or TdP (Figure
6): the Q9E substitution (glutamine to glutamate at position 9)
within the predicted extracellular portion of MiRP1; M54T
(methionine to threonine) and I57T (isoleucine to threonine)
substitutions in the predicted TM domain; and A116V (alanine to
valine) in the predicted cytoplasmic domain.  All four mutations
diminish baseline potassium flux through the MiRP1/HERG
channels: the Q9E substitution shifts the voltage dependence of
activation to more positive values; the M54T substitution
accelerates channel deactivation; and the I57T and A116V
substitutions apparently compromise unitary current magnitude
and cell surface half-life, respectively (F. Sesti, personal
communication).
Although inherited arrhythmia is rare, acquired arrhythmia is
relatively common in association with adverse reactions to
medications, drugs of abuse, and metabolic abnormalities.  As is
true of most common disorders, acquired long QT syndrome
appears to have a multifactorial basis.  Thus, patients often present
with multiple inciting factors (e.g., hypokalemia and female sex)
that act cumulatively to impede cardiac repolarization (37, 44). Of
particular clinical relevance is the increased likelihood that
individuals with a prolonged QT interval may develop arrhythmia
in response to drug intake (45, 46).  Thus, individuals harboring
100
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Figure 5.  MiRP1 associates with HERG to
generate IKr. The human gene for the α-subunit
HERG can be expressed (here in Xenopus laevis
oocytes in whole-cell mode) to generate functional
VGK channels. Co-expression of MiRP1 is required,
however, to generate a current that is typical of IKr
in cardiac myocytes. Note that MiRP1 greatly
decreases HERG-mediated currents and accelerates
channel deactivation. Cells were held at -80 mV and
depolarized for 3 s to voltages of -60 (red), -40
(green), -20 (yellow), 0 (purple), 20 (orange), and
40 (blue) mV, and were subsequently repolarized to
–100 mV.
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Figure 6.  Mutations of the MiRP1-encoding gene KCNE2 can severely
compromise VGK currents and are associated with arrhythmia. The
schematic of MiRP1 indicates disease-associated mutations. Residues
highlighted in red represent missense mutations (i.e., Q9E, M54T, I57T,
and A116V) that have been functionally characterized and clinically
associated with arrhythmia (see text for details); the residue highlighted in
blue represents the site of a polymorphism (i.e., T8A) associated with
drug-induced arrhythmia (CHO, predicted sites of glycosylation; P,
predicted sites of phosphorylation).
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the M54T, I57T, and A116V variants of MiRP1 came to clinical
attention when they ingested procainamide, oxatomide, and
quinidine, respectively, three agents that inhibit IKr channels and
delay myocardial repolarization (12). In these cases, the
corresponding KCNE2 mutations do not alter sensitivity of the
channel to the given drug. Conversely, the Q9E variant of MiRP1,
identified in a patient with a long QT interval at baseline in whom
clarithromycin had induced TdP and VF, not only affects channel
gating to reduce potassium flux, but increases sensitivity of
MiRP1/HERG channels to inhibition by the drug (10), a macrolide
antibiotic previously associated with long QT syndrome and IKr
blockade (47). The patient, moreover, was female and
hypokalemic when she developed arrhythmia, two other factors
associated with reduced IKr current density. The consequences of
KCNE2 mutations thus underscore the need to consider acquired
long QT syndrome in multifactorial terms. 
In contrast to the patients characterized by rare (less than
0.02 percent of the general population) mutations of channel
genes such as KCNE2, many more individuals appear free of an
“inherent” risk of arrhythmia (i.e., their electrocardiogram is
normal) but are nevertheless prone to acquire arrhythmia in
response to certain drugs.  In particular, the T8A polymorphism of
MiRP1 is present in ~1.6 percent of the general population, and
although it is associated with neither inherited long QT syndrome
nor changes in MiRP1/HERG channel function (10), the variant
increases sensitivity to blockade by a common antibiotic (leading
to 50% current suppression at levels of the drug present in serum)
and is implicated in drug-induced arrhythmia (12).  Thus, a
common polymorphism can carry important clinical implications
for choice of drug therapy where alternatives exist, as well as for
future drug development.
Because IKr channels appear to be particularly susceptible to
blockade by a range of drugs, including anti-arrhythmic agents,
antibiotics, antihistamines, and psychotropic drugs (48), it has
been proposed that several unique structural features of HERG
make it prone to drug blockade. These include a large internal
channel cavity bearing aromatic residues that may facilitate
binding and trapping of small molecules (49).  The structural
characteristics of MiRP1 that contribute to the susceptibility of IKr
to drug blockade have not yet been elaborated.
MiRP2, THE KCNE3 GENE PRODUCT
MiRP2 is only 103 residues long, with a short predicted
intracellular domain (Figure 7) (8, 10, 13).  In contrast to KCNE1
and KCNE2, transcripts of the KCNE3 gene (encoding MiRP2) are
most abundant in skeletal, rather than cardiac, muscle.  The
search for a pore-forming α-subunit that might partner with
MiRP2 to form native potassium currents led to Kv3.4, a VGK
channel protein prominent in skeletal muscle.  Kv3.4 was found
to be coordinately expressed with MiRP2 in rat sartorius and
murine C2C12 cell plasma membranes and to form stable
assemblies with MiRP2 that altered the biophysical and
pharmacological properties of Kv3.4 to match those of a native
muscle channel (13). 
Related to the Drosophila Shaw family of potassium channels,
homomeric Kv3.4 channels activate at supra-threshold potentials
and inactivate rapidly (i.e., A-type behavior).  These properties,
however, are not observed in skeletal muscle, although Kv3.4
protein is conspicuous. Dependence of the native current on
association with MiRP2 seems to explain this finding, at least in
part, as MiRP2/Kv3.4 channels activate at sub-threshold potentials
(with a midpoint voltage dependence ~45 mV more negative than
homomeric Kv3.4 channels), and like native channels in C2C12
skeletal muscle cells, their steady-state activity at negative voltages
is ~80-fold greater than channels that lack MiRP2 (Figure 8) (13).
MiRP2 also decreases channel sensitivity to the sea anemone toxin
BDS-II, producing an inhibition constant similar to that
manifested by native channels in muscle cells, and endows Kv3.4
subunits with a single channel conductance and rate of recovery
from inactivation typical for native channels (13). 
The observed effects of MiRP2 alter our expectations for the
role for Kv3.4 subunits in skeletal muscle physiology.  Previously,
Kv3.4 channels were hypothesized to modulate calcium currents
(owing to their supra-threshold activation) and to produce
afterhyperpolarization (due to slow recovery from inactivation),
thereby limiting action potential frequency (52). In contrast,
MiRP2/Kv3.4 channels activate at sub-threshold potentials and,
thereby, contribute to the skeletal muscle resting membrane
potential (13). Moreover, their rapid recovery from inactivation
suppresses afterhyperpolarization and minimizes cumulative
inactivation to facilitate rapid trains of action potentials (Figure 9).  
As in the case of KCNE1 (MinK) and KCNE2 (MiRP1),
mutation of the KCNE3 gene has been associated with compromised
muscle function. The familial periodic paralyses are disorders of
skeletal muscle that had previously been associated with mutations
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Figure 7.  Schematic of the MiRP2 peptide indicating a mutation
associated with familial periodic paralysis. The residue highlighted in
red represents a missense mutation (i.e., R83H) that is associated with
disease (CHO, predicted sites of glycosylation; P, predicted sites of
phosphorylation).
in the SCN4A sodium channel (53-55) and in the CACNL1A3 L-
type calcium channel (56).  Based on identification of MiRP2 and its
role in a prominent skeletal muscle current, 100 patients with
periodic paralysis but no mutations in genes previously associated
with the disease were screened for alterations in KCNE3.  Two
pedigrees with a missense mutation (producing an arginine to
histidine substitution, R83H, in MiRP2) were thereby identified; the
mutation was found only in family members with symptoms, but
not in unaffected relatives or control individuals, and resulted in
diminished potassium flux, reducing the capacity of the channels to
pass current and set resting membrane potential (13).
Although KCNE3 is the first potassium channel gene
associated with inherited periodic paralysis, the effects of R83H
MiRP2 resemble those of mutations in sodium and calcium
channels: membrane depolarization, compromised repolarization,
and diminished excitability (57). These same effects are seen in
acute periodic paralysis caused by barium toxicity, which is
thought to result from decreased potassium flux due to channel
blockade (58).  Although periodic paralyses have tended to be
grouped together according to clinical findings, the disorders are
quite heterogeneous, with overlapping signs, symptoms, and
responses to therapy; gene-based classification is now beginning to
aid in both diagnosis and treatment strategies (59, 60).
MiRP PROMISCUITY
The MiRPs have been demonstrated to interact with multiple α-
subunit partners in experimental cells. Whether this promiscuity
indicates a versatility of MiRP function in the physiology of
potassium channels remains an open question.  Whereas MinK
assembles with KCNQ1 to form cardiac IKs currents (14), MinK
antisense oligonucleotides reduced IKr currents in murine atrial
tumor cells (61), thereby suggesting an interaction between MinK
and HERG.  Indeed, MinK was found to form stable complexes
with HERG in CHO and COS cells and to double current density,
apparently by increasing the fraction of active channels in the
102
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Figure 8.  The KCNE3-encoded peptide MiRP2 associates with
the α-subunit Kv3.4 to generate VGK channel currents typical of
skeletal myocytes. 
A. The human gene for the α-subunit Kv3.4 can be expressed in
CHO cells to generate functional VGK channels. Co-expression of
MiRP2 is required, however, to generate a current that is typical of
skeletal myocytes (right); note that MiRP2 leads to sub-threshold
currents.  Cells were held at -80 mV and depolarized for 3 s to
voltages of -70 (red), -40 (green), -20 (yellow), 20 (purple), 40
(orange), 70 (blue), and 90 (black) mV. Kv3.4 currents were studied
in on-cell patches with 100 mM external KCl. 
B. Steady-state currents in patches held at –40 mV. The displayed
traces represent 18-second continuous recordings at 6 s per line.
(The patches representing expression of Kv3.4 and co-expression of
Kv3.4/MiRP2 in CHO cells contain one channel; native C2C12
myocyte patches contain three channels.)
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membrane (39).  Consistent with these findings, IKr currents were
diminished in cardiac muscle cells from mice where Kcne1 was
replaced by lacZ (62).  Nevertheless, MinK/HERG complexes do
not recapitulate the classical properties of IKr as do MiRP1/HERG
complexes, and HERG binds MiRP1 in preference to MinK (10).
Conceivably, MinK may assemble with HERG in cells in which
MiRP1 is not produced, or may influence MiRP1/HERG complexes
to alter their regulation, trafficking, or activity levels.
MiRP1 also exhibits promiscuous interactions.  In addition to
assembling with HERG to form cardiac IKr channels (10), it
associates with Kv4.2 subunits (which contribute to cardiac and
neuronal transient outward currents, Ito) to slow channel
inactivation and alter the kinetics of 4-aminopyridine blockade
(63, 64).  Again, it is unclear whether MiRP1/Kv4.2 complexes
form in native cells.  MiRP1 has also been reported to alter the
properties of KCNQ1 when the two subunits are expressed in COS
cells (65), although no such effect was seen in two studies using
Xenopus laevis oocytes (10, 66) and one using CHO cells (F. Sesti,
personal communication).  
MiRP2 appears to enjoy a particularly wide range of
interactions.  In addition to its assembly with Kv3.4 in native and
experimental cells (13), MiRP2 can be expressed along with
KCNQ1 in CHO cells to produce a channel that is open at resting
membrane potentials, and in oocytes MiRP2 suppresses currents
passed by HERG and KCNQ4 α-subunits (67, 68).
Moreover, equivalent positions in MinK and MiRP2 appear to
act similarly with their recognized pore-forming partners.  Thus,
D76N MinK (associated with long QT syndrome) alters KCNQ1
function by shifting activation to positive potentials, reducing
single-channel current amplitude, and lowering steady-state open
probability; D90N MiRP2 (the analogous mutation) affects Kv3.4
and KCNQ1 in the same ways (17, 69).  Similarly, R83H MiRP2
(associated with periodic paralysis) shifts activation to positive
potentials, reduces unitary conductance, and lowers steady-state
open probability of complexes with Kv3.4 and KCNQ1, and the
equivalent mutation in MinK (K69H) has similar effects on
KCNQ1 channels (69). Remarkably, studies with MinK/MiRP2
chimeras and KCNQ1 have revealed that a three-residue stretch in
the TM domain (amino acids 57–59 in MinK, 71–73 in MiRP2) is
necessary and sufficient to account for contrasting effects of the
two peptides on channel activation (68).  Although these results
suggest that each MiRP combines with different pore-forming
partners to produce similar effects, MiRP2 suppresses HERG
currents yet increases flux through KCNQ1 and Kv3.4 channels
(13, 67). 
CONCLUSIONS AND FUTURE DIRECTIONS
The clinical classification, prognosis, and treatment for patients
with ion channel defects are often challenging due to
overlapping signs and symptoms. Nevertheless, the clear
correlations among mutations of KCNE genes, patient
presentation, and disruption of potassium currents has
identified important roles for MiRPs in normal physiology and
disease. Thus, patients with long QT syndrome can now be
assessed in terms of genotype, in addition to clinical
presentation and response to drug therapy, and treatment of
patients with periodic paralysis has benefited from the use of
genotype as a criterion for therapeutic approach (70, 60).
The multifactorial basis of drug-induced arrhythmia has made
the identification of patients at risk for adverse drug reactions
rather difficult. Gene-based diagnosis now presents itself as a
viable option. Indeed, as the database of allelic variants grows,
preprescription genotyping will become a consideration for
avoiding drug-induced pathology.  Moreover, because MiRP
peptides alter the pharmacology of cloned VGK channel α-
subunits to recapitulate currents typical of native cells, drug
development programs may benefit from study of heteromeric
complexes that include both a MiRP and its cognate α-subunit. 
The essential role of MiRPs in native channels is evident in
congenital disorders arising from KCNE mutations. Nevertheless, it
is important to note that animal models and human physiology
often differ substantially.  Kcne1 knockout (-/-) mice, for example,
display loss of MinK, disrupted potassium secretion, degeneration
of the inner ear, and profound deafness (41, 71), accurately
modeling in these respects patients with JLNS; the mice, however,
have only minor changes in cardiovascular function (62, 72).
Figure 9.  MiRP2 accelerates inactivation recovery of Kv3.4 channels.
Representative low current density on membrane patches from CHO cells
expressing Kv3.4 or MiRP2/Kv3.4 cannels during a train of 1-s repetitive
pulses to +60 mV from a holding voltage of –80 mV (protocol in inset).
Wherease Kv3.4 channels show re-openings at –80 mV following
depolarization as they recover slowly from inactivation, MiRP2/Kv3.4
channels recover more quickly and re-openings are not visible. 
Kv3.4
MiRP2
+Kv3.4
Thus, action potentials from Kcne1 (-/-) knockout mice remain
normal, whereas long QT syndrome and life-threatening
arrhythmia are associated with KCNE1 missense mutations in
humans.  Similarly, disruption of KCNQ1 in mice (encoding the
partner for MinK in IKs formation) results in vestibular deafness
but not in electrocardiographic abnormalities (47), although a
subsequent report describes conditions similar to JLNS, with both
inner ear and cardiac dysfunction (75).  Interspecies differences
have been attributed to low levels of MinK in adult mice and to
the relatively minor role for IKr and IKs in cardiac repolarization
in newborn animals (62). 
Thus far, MinK/KCNQ1, MiRP1/HERG and MiRP2/Kv3.4 are
the recognized MiRP/α-subunit partnerships that have been
correlated to native currents and disease.  However, as MinK and
MiRP2 interact with KCNQ1, and MinK, MiRP1, and MiRP2 all
interact with HERG, and all three MiRPs enjoy widespread tissue
expression, these recognized partnerships may be the tip of the
iceberg.  Indeed, there is no reason to presume that MiRP
interactions are precluded with calcium-activated potassium
channels, cyclic–nucleotide gated channels, inward rectifier
potassium channels, and even two-P-domain potassium channels.
Among many questions that remain to be answered are the rules
that govern subunit specificity and whether complexes can contain
more than one type of MiRP.  As evidenced by their role in health
and disease, these diminutive subunits appear to be more powerful
than might be expected based on their size.
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